Santen Pharmaceutical First-Half Revenue Rises 3.9% to ¥143.289 Billion
Photo: TokenPost
Santen Pharmaceutical recorded a 3.9% increase in revenue to ¥143.289 billion for the six months ended Sept. 30, compared with the year-earlier period, as operating and net profit also advanced. Revenue was ¥137.879 billion a year earlier. Operating profit increased 8.4% to ¥19.411 billion, and net profit rose 11.7% to ¥15.478 billion. Basic earnings per share was ¥48.05, and diluted earnings per share was ¥47.97. The interim results were prepared under International Financial Reporting Standards (IFRS) and cover the six-month period, rather than the September quarter alone. Santen left its forecast for the fiscal year ending March 31, 2027, unchanged.
Source: TokenPost
